Potential Uses of Sacubitril/Valsartan: Need for Data on Efficacy and Safety.
Aminobutyrates
/ pharmacology
Angiotensin Receptor Antagonists
/ pharmacology
Angiotensin-Converting Enzyme Inhibitors
/ pharmacology
Animals
Biphenyl Compounds
Drug Combinations
Heart Failure
/ drug therapy
Humans
Stroke Volume
/ drug effects
Tetrazoles
/ pharmacology
Valsartan
/ pharmacology
Ventricular Dysfunction, Left
/ drug therapy
Journal
American journal of cardiovascular drugs : drugs, devices, and other interventions
ISSN: 1179-187X
Titre abrégé: Am J Cardiovasc Drugs
Pays: New Zealand
ID NLM: 100967755
Informations de publication
Date de publication:
Feb 2019
Feb 2019
Historique:
pubmed:
23
10
2018
medline:
30
5
2019
entrez:
23
10
2018
Statut:
ppublish
Résumé
Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers have been the cornerstone for the treatment of heart failure (HF) with reduced ejection fraction for decades. According to recent and promising studies, sacubitril/valsartan (SV) might be efficient in alternative indications in the area of HF with preserved left ventricular ejection fraction, chronic kidney disease, and so on. This review briefly summarizes these promising therapeutic options regarding SV and the potential limits and pitfalls for its use in routine practice (due to cognitive uncertainties).
Identifiants
pubmed: 30345485
doi: 10.1007/s40256-018-0306-z
pii: 10.1007/s40256-018-0306-z
doi:
Substances chimiques
Aminobutyrates
0
Angiotensin Receptor Antagonists
0
Angiotensin-Converting Enzyme Inhibitors
0
Biphenyl Compounds
0
Drug Combinations
0
Tetrazoles
0
Valsartan
80M03YXJ7I
sacubitril and valsartan sodium hydrate drug combination
WB8FT61183
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM